(January 26, 2017)
daacro received further EU-funding to participate in the Eurostars-project named “ActiveNutraLife – A new complementary medicine approach for the management of chemotherapy side effects,” from November 2016 until October 2019. This project aims at designing and testing in clinical studies a new complementary medicine approach to speed up the recovery of haematological cancer patients in a post-chemotherapy phase.
daacro’s Saliva Lab Trier, where new promising biomarkers will be searched and analyzed, will do a major part of the work for this project. daacro’s Saliva Lab is a Salimetrics Center of Excellence Laboratory and closely cooperates with Salimetrics, who is widely regarded as a global leader in developing assays for salivary bioscience
The ActiveNutraLife approach combines a nutraceutical supplementation, a remotely accessible adapted physical activity program and a personalized stress and fatigue diagnostic tool, allowing acceleration and monitoring of the individual recovery. An “ActiveNutraLife” kit containing these services will be offered by means of the web and is of interest to health insurance providers.
To achieve this aim, daacro partners with two French companies – Bionov, responsible for the nutraceutical supplementation (a unique melon extract) and V@si, responsible for the adapted physical activity program.
daacro’s responsibility in this project is the development of the diagnostic tool which will be an offspring of daacro’s neuropattern™. neuropattern™ is an individualized diagnostic tool for stress related disorders, which allows differentiation between 13 stress-related endophenotypes called “neuropattern”. The adapted version “HEMO-neuropattern” will concentrate on fatigue-related endophenotypes.
In a first step, daacro will work on adapting and further developing the existing neuropattern™ diagnostic and on finding new biomarkers to better identify subgroups of haematological cancer patients (“HEMO-neuropattern”). Next, in a clinical trial performed by Hospital CHU Montpellier and further sites in South France, “HEMO-neuropattern” will be tested on efficacy of its personalized recommendations for better management of chemotherapy-induced side effects.
Salimetrics’ assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health and immune function. Founded in 1998 by Douglas A. Granger, Ph.D., Salimetrics, LLC supports CROs, pharmaceuticals, academic researchers and the immunodiagnostic industry around the world with innovative immunoassay products, non-invasive saliva collection methods, and laboratory testing services.
neuropattern™ is a diagnostic test that was developed in Trier, Germany. It provides a comprehensive assessment of neuroendocrine, psychosocial, and physical health interactions that emanate from the brain and body under stress. neuropattern™ is used to differentiate endophenotypes in patients with similar symptomatology and thus, this the procedure is particularly suited for individualized diagnostics and pharmacogenetic studies.
Read this article on PR Web